ep organ growth improv
great start toughest comp track exceed
expect improv growth throughout rest year rais investor
confid back continu see street concern
compani deliveri busi overblown md guid
equat compound-annual-growth-rate comp get easier quarter
view strength underli growth across portfolio improv
momentum md standout perform pharma improv margin
attract setup out-performance next month
reiter outperform rate rais target
solid margin execut in-lin rptd sale net cog vs
estimate lower non-op incom tax share
partial off-set sg drive upsid vs estimate vs con
op mgn bp estimate bp y/i
ep op mgn guid rais organ sale growth guid unch
ep guid rais bottom-end op mgn guid rais
bp organ sale growth guid remain cc
valuat target price previous base
previous project ntm ebitda forward bil
unchang risk includ key product delay failur progress lrp
goal growth margin potenti new litig regulatori
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
inc global manufactur provid
diversifi healthcar suppli equip area renal
hospit product
price apr rate outperform target price analyst matt miksic
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
one-year valuat scenario base
ev/ebitda ebitda bil
scenario base high-growth segment grow
growth grow
one-year valuat grey scenario base
ev/ebitda grey ebitda bil
grey scenario base high-growth segment grow
growth grow
 close
addit detail takeaway
renal mil mil y/i cc organ vs
perform quarter led strong pd therapi patient volum
increas hsd msd ww on-going roll-out amia kaguya
japan claria europ drove growth neg growth expect
due bax exit in-cent hd bloodlin busi mil adjust
underli growth renal busi ww
compani expect renal grow cc organ basi reflect
continu momentum pd partial off-set lower sale center hd relat
lower sale low-margin distribut bloodlin compani exit third-parti
acut therapi mil mil y/i cc organ
acut therapi grew organ despit tough comp last year compani
benefit flu season mil benefit due flu-rel sale
februari compani also announc nanthealth digit health solut
avail connect prismaflex hospit system compani
expect acut therapi grow cc organ basi driven launch
deliveri mil mil y/i cc organ vs
manag expect deliveri perform improv sequenti
compani work toward recaptur svp share well continu adopt
spectrum iq pump north america evo iq pump ou manag expect
growth acceler throughout year compani anniversari stock
impact recaptur svp share execut new pump launch improv product
avail ou compani expect medic deliveri grow cc
organ expect sequenti improv throughout year
pharmaceut mil mil y/i cc organ
growth driven contribut clari inject well launch new
molecul includ recent launch dexm epti premix
addit increas demand pharmaci compound servic along growth
anesthesia drove upsid quarter pharma sale partial off-set mil
lower sale brevibloc cyclo compani expect pharmaceut
declin lsd cyclo sale mil vs previou guidanc mil
clinic nutrit mil mil y/i cc organ
compani continu work return demand impact product pre-
hurrican level ou declin quarter result shift order apac
emea later year compani expect sequenti improv
growth rate compani expect clinic nutrit grow cc
advanc surgeri mil mil y/i cc organ
dd growth quarter driven strength result last year
recothrom preveleak acquisit mil contribut well increas
sale hemostat sealant compani expect advanc surgeri
grow cc organ basi
mil in-lin y/i cc organ vs cse
perform driven increas demand contract manufactur servic
easier y/i comp compani expect declin lsd msd
cc organ basi
 op margin bp estim bp y/i
in-lin sale net cog rel estim lower non-op incom
tax share count partial off-set sg drive upsid
cse ep gross margin in-lin estim
compani maintain organ sale growth guidanc cc
increas ep guidanc bottom-end oper
margin outlook increas bp
compani guid cc growth organ ep
sale
sale
estimate
ep
sale
sale
estimate
charl martineau univers toronto chang model
lower sale estim rais ep estim in-
line new guidanc beyond make minor chang top-lin
estim bring ep estim slightli
figur chang model
target price previous base previous project
ntm ebitda one-year forward bil unchang new target multipl roughli
line stock current trade multipl risk includ key product delay
failur progress lrp goal growth margin potenti new litig
regulatori qualiti issu
charl martineau univers toronto compani mention price
